ID: ALA1091041

Max Phase: Preclinical

Molecular Formula: C15H9BrN2O2

Molecular Weight: 329.15

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  O=C1OC(c2cccc(Br)c2)=N/C1=C\c1cccnc1

Standard InChI:  InChI=1S/C15H9BrN2O2/c16-12-5-1-4-11(8-12)14-18-13(15(19)20-14)7-10-3-2-6-17-9-10/h1-9H/b13-7-

Standard InChI Key:  UBEOAFQCFKQVDY-QPEQYQDCSA-N

Associated Targets(Human)

Death-associated protein kinase 3 2108 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 329.15Molecular Weight (Monoisotopic): 327.9847AlogP: 3.19#Rotatable Bonds: 2
Polar Surface Area: 51.55Molecular Species: NEUTRALHBA: 4HBD: 0
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 4.68CX LogP: 3.39CX LogD: 3.39
Aromatic Rings: 2Heavy Atoms: 20QED Weighted: 0.63Np Likeness Score: -1.54

References

1. Okamoto M, Takayama K, Shimizu T, Muroya A, Furuya T..  (2010)  Structure-activity relationship of novel DAPK inhibitors identified by structure-based virtual screening.,  18  (7): [PMID:20206532] [10.1016/j.bmc.2010.02.018]

Source